BioCytics
BioCytics is a biotechnology company focused on cancer immunotherapy, dedicated to researching and developing novel cellular therapies for diseases and accelerating personalized medicine to market. Located in Huntersville, North Carolina, it collaborates with industry leaders in biospecimen banking, cell manufacturing, and clinical trials, with a mission to provide comprehensive patient care and develop therapies for solid tumors. The company is engaged in diverse immune effector cell research, leveraging the intrinsic specificity of autologous immune cells to treat solid tumors, and is actively seeking collaborations for the development of novel and combination therapies in oncology.
Industries
Nr. of Employees
small (1-50)
BioCytics
Products
Integrated clinical informatics platform
A digitally integrated platform for cellular therapy trials combining an openEHR-based EMR, EDC/CDM for agile eCRF design and real-time validation, laboratory/biobank documentation and inventory tracking, and CTMS for trial administration.
Patient Derived Tumor
Complex, three-dimensional structures derived from patient tumor tissues that mimic the heterogeneity and microenvironment of the patient's tumor.
Patient Derived Tumor Spheroids
Three-dimensional aggregates of tumor cells that form a spherical shape for studying tumor biology and drug response.
Tumor Cells
Tumor cells derived from fresh core biopsies, meticulously expanded and nurtured, with supplementary tumor samples available in archived block or slide formats.
BioCytics Immune Fraction #1
An immuno-oncology tumor treatment protocol and cellular therapy designed to be manufactured at the point of care for treating solid tumors.
CellSearch CTC enumeration with additional biomarkers such as
Specialized circulating tumor cell analysis combining CellSearch enumeration with Prostate-Specific Membrane Antigen (PSMA) biomarker detection.
Integrated clinical informatics platform
A digitally integrated platform for cellular therapy trials combining an openEHR-based EMR, EDC/CDM for agile eCRF design and real-time validation, laboratory/biobank documentation and inventory tracking, and CTMS for trial administration.
Patient Derived Tumor
Complex, three-dimensional structures derived from patient tumor tissues that mimic the heterogeneity and microenvironment of the patient's tumor.
Patient Derived Tumor Spheroids
Three-dimensional aggregates of tumor cells that form a spherical shape for studying tumor biology and drug response.
Tumor Cells
Tumor cells derived from fresh core biopsies, meticulously expanded and nurtured, with supplementary tumor samples available in archived block or slide formats.
BioCytics Immune Fraction #1
An immuno-oncology tumor treatment protocol and cellular therapy designed to be manufactured at the point of care for treating solid tumors.
CellSearch CTC enumeration with additional biomarkers such as
Specialized circulating tumor cell analysis combining CellSearch enumeration with Prostate-Specific Membrane Antigen (PSMA) biomarker detection.
Services
Custom development and optimization of cell processing workflows and analytical assays to support preclinical development and IND-enabling activities.
cGMP-compliant production of cell therapy products in ISO-classified cleanrooms using closed-system and automated platforms to support Phase I studies and point-of-care models.
End-to-end services for feasibility, initiation, execution and completion of early-phase immuno-oncology and cell therapy clinical trials, including regulatory and safety oversight.
On-site high-complexity clinical laboratory testing covering routine and specialized assays with external proficiency enrollment and accredited quality systems.
Research-use analytical testing including immune phenotyping, potency and cytotoxicity assays, instrument/reagent qualification, and custom assay development to support discovery and IND-enabling work.
IRB-approved biospecimen collection, long-term controlled storage, and sourcing of annotated samples (leukapheresis, PBMCs, tumor tissue, CTCs, biofluids) for translational research.
Custom development and optimization of cell processing workflows and analytical assays to support preclinical development and IND-enabling activities.
cGMP-compliant production of cell therapy products in ISO-classified cleanrooms using closed-system and automated platforms to support Phase I studies and point-of-care models.
End-to-end services for feasibility, initiation, execution and completion of early-phase immuno-oncology and cell therapy clinical trials, including regulatory and safety oversight.
On-site high-complexity clinical laboratory testing covering routine and specialized assays with external proficiency enrollment and accredited quality systems.
Research-use analytical testing including immune phenotyping, potency and cytotoxicity assays, instrument/reagent qualification, and custom assay development to support discovery and IND-enabling work.
IRB-approved biospecimen collection, long-term controlled storage, and sourcing of annotated samples (leukapheresis, PBMCs, tumor tissue, CTCs, biofluids) for translational research.
Expertise Areas
- Early-phase cell and gene therapy manufacturing
- Process and assay development for IND-enabling programs
- Biobanking, specimen procurement and cold-chain distribution
- Translational immunology and immune phenotyping
Key Technologies
- Multicolor flow cytometry
- qRT-PCR
- Live-cell imaging
- Multiplex cytokine/protein assays
News & Updates
Dr. Powderly discusses advancements in immunotherapy, TILs, and clinical trials at Carolina BioOncology.
Dr. Powderly discusses advancements in immunotherapy, TILs, and clinical trials at Carolina BioOncology.